hydrochlorothiazide has been researched along with Hyperglycemia in 33 studies
Hydrochlorothiazide: A thiazide diuretic often considered the prototypical member of this class. It reduces the reabsorption of electrolytes from the renal tubules. This results in increased excretion of water and electrolytes, including sodium, potassium, chloride, and magnesium. It is used in the treatment of several disorders including edema, hypertension, diabetes insipidus, and hypoparathyroidism.
hydrochlorothiazide : A benzothiadiazine that is 3,4-dihydro-2H-1,2,4-benzothiadiazine 1,1-dioxide substituted by a chloro group at position 6 and a sulfonamide at 7. It is diuretic used for the treatment of hypertension and congestive heart failure.
Hyperglycemia: Abnormally high BLOOD GLUCOSE level.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The combination of hydrochlorothiazide and amiloride has been used in a group of patients diagnosed as having essential hypertension." | 7.66 | A fixed combination of hydrochlorothiazide and amiloride for the treatment of essential hypertension. ( Alcazar, JM; Diaz, VP; Jarillo, MD; Millet, VG; Rodicio, JL; Ruilope, L, 1980) |
| "Two patients developed diabetic coma when taking a combination of a thiazide diuretic and propranolol." | 7.66 | Hyperglycemia and diabetic coma: possible relationship to diuretic-propranolol therapy. ( Bouma, DJ; Nardone, DA, 1979) |
| " In multivariable Cox analyses, adjusting for randomized treatment, age, sex, race, prior anti-hypertensive therapy, baseline uric acid, serum creatinine and glucose entered as standard covariates, and in-treatment non-HDL cholesterol, Cornell product left ventricular hypertrophy, diastolic and systolic pressure, BMI, hydrochlorothiazide and statin use as time-varying covariates, the lowest quartile of in-treatment HDL remained associated with a nearly 9-fold increased risk of new diabetes (hazard ratio 8." | 5.17 | In-treatment HDL cholesterol levels and development of new diabetes mellitus in hypertensive patients: the LIFE Study. ( Dahlöf, B; Devereux, RB; Hille, DA; Kjeldsen, SE; Lindholm, LH; Okin, PM; Wiik, BP, 2013) |
| "We assessed adverse metabolic effects of atenolol and hydrochlorothiazide among hypertensive patients with and without abdominal obesity using data from a randomized, open-label study of hypertensive patients without evidence of cardiovascular disease or diabetes mellitus." | 5.14 | Impact of abdominal obesity on incidence of adverse metabolic effects associated with antihypertensive medications. ( Beitelshees, AL; Boerwinkle, E; Chapman, AB; Cooper-DeHoff, RM; Gong, Y; Gums, JG; Hall, K; Johnson, JA; Parekh, V; Turner, ST; Wen, S; Zineh, I, 2010) |
| "Changes in serum potassium and serum glucose levels were not correlated in individuals receiving hydrochlorothiazide monotherapy; thus maintenance of normal potassium levels may not attenuate the risk of thiazide diuretic-induced hyperglycemia." | 3.75 | Lack of correlation between thiazide-induced hyperglycemia and hypokalemia: subgroup analysis of results from the pharmacogenomic evaluation of antihypertensive responses (PEAR) study. ( Anderson, SD; Bailey, K; Boerwinkle, E; Chapman, A; Cooper-Dehoff, RM; Feng, H; Gong, Y; Gums, JG; Hall, KL; Johnson, JA; Schwartz, GL; Smith, SM; Turner, ST; Wen, S, 2009) |
| " Potassium supplementation improves their insulin resistance and hypertension, whereas allopurinol reduces serum levels of uric acid and ameliorates hypertension, hypertriglyceridemia, hyperglycemia, and insulin resistance." | 3.74 | Thiazide diuretics exacerbate fructose-induced metabolic syndrome. ( Johnson, RJ; Mu, W; Nakagawa, T; Reungjui, S; Roncal, CA; Sirivongs, D; Srinivas, TR, 2007) |
| "The combination of hydrochlorothiazide and amiloride has been used in a group of patients diagnosed as having essential hypertension." | 3.66 | A fixed combination of hydrochlorothiazide and amiloride for the treatment of essential hypertension. ( Alcazar, JM; Diaz, VP; Jarillo, MD; Millet, VG; Rodicio, JL; Ruilope, L, 1980) |
| "Two patients developed diabetic coma when taking a combination of a thiazide diuretic and propranolol." | 3.66 | Hyperglycemia and diabetic coma: possible relationship to diuretic-propranolol therapy. ( Bouma, DJ; Nardone, DA, 1979) |
| "Insulin resistance is associated with a number of risk factors for atherosclerosis, including glucose intolerance, hypertension, and dyslipidemia." | 2.38 | Insulin resistance. An often unrecognized problem accompanying chronic medical disorders. ( Bell, DS, 1993) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 23 (69.70) | 18.7374 |
| 1990's | 2 (6.06) | 18.2507 |
| 2000's | 2 (6.06) | 29.6817 |
| 2010's | 6 (18.18) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Okin, PM | 1 |
| Hille, DA | 1 |
| Wiik, BP | 1 |
| Kjeldsen, SE | 1 |
| Lindholm, LH | 1 |
| Dahlöf, B | 1 |
| Devereux, RB | 1 |
| Gong, Y | 4 |
| McDonough, CW | 1 |
| Beitelshees, AL | 3 |
| Karnes, JH | 1 |
| O'Connell, JR | 1 |
| Turner, ST | 4 |
| Chapman, AB | 2 |
| Gums, JG | 4 |
| Bailey, KR | 1 |
| Boerwinkle, E | 4 |
| Johnson, JA | 4 |
| Cooper-DeHoff, RM | 4 |
| Moore, MJ | 1 |
| Hou, W | 1 |
| Hall, K | 2 |
| Schmidt, SO | 1 |
| Curry, RW | 1 |
| Chapman, A | 2 |
| Schwartz, GL | 2 |
| Bailey, K | 2 |
| Smith, SM | 1 |
| Anderson, SD | 1 |
| Wen, S | 2 |
| Hall, KL | 1 |
| Feng, H | 1 |
| Manrique, C | 1 |
| Johnson, M | 1 |
| Sowers, JR | 2 |
| Zineh, I | 1 |
| Parekh, V | 1 |
| Ofili, EO | 1 |
| Zappe, DH | 1 |
| Purkayastha, D | 1 |
| Samuel, R | 1 |
| NICOLE, JC | 1 |
| PULVER, W | 1 |
| WOLFF, FW | 2 |
| PARMLEY, WW | 1 |
| GROSSI, F | 1 |
| OKUN, R | 1 |
| WILSON, WR | 1 |
| GELFAND, MD | 1 |
| LYON, AF | 1 |
| DEGRAFF, AC | 1 |
| CHAZAN, JA | 1 |
| BOSHELL, BR | 1 |
| HALPRIN, H | 1 |
| Reungjui, S | 1 |
| Roncal, CA | 1 |
| Mu, W | 1 |
| Srinivas, TR | 1 |
| Sirivongs, D | 1 |
| Johnson, RJ | 1 |
| Nakagawa, T | 1 |
| Foy, JM | 3 |
| Wales, JK | 1 |
| Viktora, JK | 1 |
| Perry, HM | 1 |
| Ruilope, L | 1 |
| Alcazar, JM | 1 |
| Diaz, VP | 1 |
| Jarillo, MD | 1 |
| Millet, VG | 1 |
| Rodicio, JL | 1 |
| Bell, DS | 1 |
| Amery, A | 1 |
| Berthaux, P | 1 |
| Bulpitt, C | 1 |
| Deruyttere, M | 1 |
| de Schaepdryver, A | 1 |
| Dollery, C | 1 |
| Fagard, R | 1 |
| Forette, F | 1 |
| Hellemans, J | 1 |
| Lund-Johansen, P | 1 |
| Mutsers, A | 1 |
| Tuomilehto, J | 1 |
| Nardone, DA | 1 |
| Bouma, DJ | 1 |
| Takebe, K | 1 |
| Onuma, T | 1 |
| Dornhorst, A | 1 |
| Powell, SH | 1 |
| Pensky, J | 1 |
| Glezer, GA | 1 |
| Levinzon, AM | 1 |
| Kurilova, LP | 1 |
| Korobenko, GN | 1 |
| Meng, K | 1 |
| Kroneberg, G | 1 |
| Sitt, R | 1 |
| Senft, G | 1 |
| Losert, W | 1 |
| Kaess, H | 1 |
| Diamond, MT | 1 |
| Furman, BL | 2 |
| Sikka, KK | 1 |
| Nath, K | 1 |
| Agarwal, SN | 1 |
| Tandon, AP | 1 |
| Káldor, A | 1 |
| Pogátsa, G | 1 |
| Bossini, A | 1 |
| Bologna, E | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR)[NCT00246519] | Phase 4 | 1,701 participants (Actual) | Interventional | 2005-10-31 | Completed | ||
| A 16-week Double-blind, Randomized, Multicenter, Force-titration Study to Evaluate the Antihypertensive Efficacy of Valsartan/Hydrochlorothiazide (HCTZ) Therapy Compared to HCTZ Based Therapy in Obese, Hypertensive Patients[NCT00439738] | Phase 4 | 412 participants (Actual) | Interventional | 2006-12-31 | Completed | ||
| Uric Acid and Hypertension in African Americans[NCT00241839] | Phase 3 | 150 participants (Actual) | Interventional | 2005-08-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT00246519)
Timeframe: baseline to 18 weeks of treatment
| Intervention | mmHg (Mean) |
|---|---|
| Atenolol +HCTZ Arm | -12.06 |
| HCTZ + Atenolol | -13.33 |
After a 75 gram anhydrous glucose challenge 2 hours after an oral glucose tolerance test (NCT00439738)
Timeframe: Week 16
| Intervention | mg/dL (Mean) | |||||
|---|---|---|---|---|---|---|
| Baseline visit (0 minutes) | Week 16 (0 minutes) | Change from baseline to week 16 (0 minutes) | Baseline visit (120 minutes) | Week 16 (120 minutes) | Change from baseline to week 16 (120 minutes) | |
| HCTZ +Amlodipine | 99.4 | 102.8 | 3.4 | 127.7 | 146.5 | 18.9 |
| Valsartan/HCTZ (Hydrochlorothiazide) | 98.0 | 98.1 | -0.5 | 123.9 | 126.3 | 2.1 |
After a 75 gram anhydrous glucose challenge 2 hours after an oral glucose tolerance test (NCT00439738)
Timeframe: Week 16
| Intervention | mg/dL (Mean) | |||||
|---|---|---|---|---|---|---|
| Baseline visit (0 minutes) | Week 16 (0 minutes) | Change from baseline to week 16 (0 minutes) | Baseline visit (120 minutes) | Week 16 (120 minutes) | Change from baseline to week 16 (120 minute) | |
| HCTZ +Amlodipine | 20.37 | 23.62 | 3.67 | 95.95 | 120.01 | 28.07 |
| Valsartan/HCTZ (Hydrochlorothiazide) | 19.66 | 23.45 | 3.41 | 92.04 | 116.04 | 24.68 |
After a 75 gram anhydrous glucose challenge 2 hours after an oral glucose tolerance test (NCT00439738)
Timeframe: Week 16
| Intervention | mg/dL (Mean) | |||||
|---|---|---|---|---|---|---|
| Baseline visit (0 minutes) | Week 16 (0 minutes) | Change from baseline to week 16 (0 minutes) | Baseline visit (120 minutes) | Week 16 (120 minutes) | Change from baseline to week 16 (120 minutes) | |
| HCTZ +Amlodipine | 0.47 | 0.47 | 0.00 | 0.10 | 0.10 | -0.01 |
| Valsartan/HCTZ (Hydrochlorothiazide) | 0.45 | 0.46 | 0.01 | 0.11 | 0.10 | -0.01 |
(NCT00439738)
Timeframe: Baseline to Weeks 4, 8, 12 and 16
| Intervention | mm Hg (Mean) | |||||
|---|---|---|---|---|---|---|
| Baseline | Week 4 | Week 8 | Week 12 | Week 16 | Change from baseline to week 16 | |
| HCTZ +Amlodipine | 93.6 | 87.6 | 85.1 | 82.8 | 80.9 | -12.7 |
| Valsartan/HCTZ (Hydrochlorothiazide) | 94.9 | 85.7 | 81.9 | 81.1 | 80.8 | -14.0 |
(NCT00439738)
Timeframe: Baseline to Week 8
| Intervention | mm Hg (Mean) | ||
|---|---|---|---|
| Baseline | Week 8 | Change from baseline | |
| HCTZ +Amlodipine | 159.0 | 137.5 | -21.5 |
| Valsartan/HCTZ (Hydrochlorothiazide) | 159.7 | 131.2 | -28.6 |
Mean sitting systolic blood pressure/mean sitting diastolic blood pressure < 140/90 mm Hg (NCT00439738)
Timeframe: Weeks 4, 8, 12 16 and End of Study (for patients that did not complete the last visit at week 16)
| Intervention | participants (Number) | ||||
|---|---|---|---|---|---|
| Week 4 | Week 8 | Week 12 | Week 16 | End of study | |
| HCTZ +Amlodipine | 69 | 102 | 112 | 140 | 146 |
| Valsartan/HCTZ (Hydrochlorothiazide) | 91 | 123 | 122 | 124 | 133 |
Mean sitting systolic blood pressure/mean sitting diastolic blood pressure < 130/80 mm Hg (NCT00439738)
Timeframe: Week 4, 8, 12, 16, End of Study (for patients that did not complete the last visit at week 16)
| Intervention | participants (Number) | ||||
|---|---|---|---|---|---|
| Week 4 | Week 8 | Week 12 | Week 16 | End of Study | |
| HCTZ +Amlodipine | 18 | 23 | 46 | 65 | 68 |
| Valsartan/HCTZ (Hydrochlorothiazide) | 33 | 59 | 57 | 62 | 68 |
"The Diastolic BP was taken at Baseline and after 8-10 weeks of treatment or placebo while on chlorthalidone and potassium chloride. The blood pressure was measured according to Shared Care protocol: 15 minutes of quiet, undisturbed rest with three BP measurements obtained subsequently at 5 minute intervals.~The mean of the second and third reading was the value used for analysis for both the Baseline measurement and the measurement after 8 - 10 weeks of treatment. The dependent variable is baseline value minus ending value.~Measures are in millimeters of mercury (mm hg)" (NCT00241839)
Timeframe: Measured at 8-10 weeks on allopurinol / placebo
| Intervention | mm Hg (Mean) |
|---|---|
| A (Allopurinol) | 3.44 |
| B (Placebo) | -0.83 |
Subjects had 24 hr blood pressure monitoring (ABPM) at baseline and treatment end. The readings were averaged and the changes from baseline to treatment end were compared. (NCT00241839)
Timeframe: Baseline and end of treatment (8-10 weeks on allopurinol / placebo)
| Intervention | mm Hg (Mean) |
|---|---|
| A (Allopurinol) | -5.9 |
| B (Placebo) | 0.90 |
"The systolic BP was taken at Baseline and after 8-10 weeks of treatment on placebo, while on chlorthalidone and potassium chloride. The blood pressure was measured according to Shared Care protocol: 15 minutes of quiet, undisturbed rest with three BP measurements obtained subsequently at 5 minute intervals.~The mean of the second and third reading was the value used for analysis for both the Baseline measurement and the measurement after 8 - 10 weeks of treatment. The dependent variable is baseline value minus ending value.~Measures are in millimeters of mercury (mm hg)" (NCT00241839)
Timeframe: Measured at 8-10 weeks on allopurinol or placebo
| Intervention | mm Hg (Mean) |
|---|---|
| A (Allopurinol) | 0.21 |
| B (Placebo) | -0.95 |
Subjects on allopurinol are expected to lower their uric acid levels relative to placebo. (NCT00241839)
Timeframe: Baseline UA levels compared to end of treatment levels (8-10 weeks on allopurinol / placebo)
| Intervention | mg/dl (Mean) |
|---|---|
| A (Allopurinol) | 2.29 |
| B (Placebo) | 0.14 |
2 reviews available for hydrochlorothiazide and Hyperglycemia
| Article | Year |
|---|---|
[2 IMPORTANT SIDE-EFFECTS OF SALURETIC DRUGS: HYPERURICEMIC AND HYPERGLYCEMIC SYNDROMES].
Topics: Acetazolamide; Blood Chemical Analysis; Chlorothiazide; Chlorthalidone; Diuretics; Humans; Hydrochlo | 1963 |
Insulin resistance. An often unrecognized problem accompanying chronic medical disorders.
Topics: Acanthosis Nigricans; Adrenergic alpha-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Arteri | 1993 |
8 trials available for hydrochlorothiazide and Hyperglycemia
| Article | Year |
|---|---|
In-treatment HDL cholesterol levels and development of new diabetes mellitus in hypertensive patients: the LIFE Study.
Topics: Aged; Antihypertensive Agents; Atenolol; Cholesterol, HDL; Comorbidity; Diabetes Mellitus, Type 2; D | 2013 |
PROX1 gene variant is associated with fasting glucose change after antihypertensive treatment.
Topics: Adrenergic beta-Antagonists; Adult; Antihypertensive Agents; Atenolol; Blood Glucose; Drug Therapy, | 2014 |
Predictors for glucose change in hypertensive participants following short-term treatment with atenolol or hydrochlorothiazide.
Topics: Adrenergic beta-1 Receptor Antagonists; Adult; Antihypertensive Agents; Atenolol; Blood Glucose; Coh | 2014 |
Impact of abdominal obesity on incidence of adverse metabolic effects associated with antihypertensive medications.
Topics: Adolescent; Adult; Aged; Antihypertensive Agents; Atenolol; Diabetes Mellitus; Drug Therapy, Combina | 2010 |
Antihypertensive and metabolic effects of Angiotensin receptor blocker/diuretic combination therapy in obese, hypertensive African American and white patients.
Topics: Adult; Aged; Aged, 80 and over; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensiv | 2013 |
The effect of hydrochlorothiazide in normal subjects receiving high fat or high carbohydrate diets.
Topics: Blood Glucose; Dietary Carbohydrates; Dietary Fats; Diuretics; Fatty Acids, Nonesterified; Female; G | 1967 |
Glucose intolerance during diuretic therapy. Results of trial by the European Working Party on Hypertension in the Elderly.
Topics: Aged; Blood Glucose; Clinical Trials as Topic; Female; Follow-Up Studies; Glucose Tolerance Test; Hu | 1978 |
Aggravation by propranolol of hyperglycaemic effect of hydrochlorothiazide in type II diabetics without alteration of insulin secretion.
Topics: Aged; Blood Glucose; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Synergism; Drug Thera | 1985 |
23 other studies available for hydrochlorothiazide and Hyperglycemia
| Article | Year |
|---|---|
Lack of correlation between thiazide-induced hyperglycemia and hypokalemia: subgroup analysis of results from the pharmacogenomic evaluation of antihypertensive responses (PEAR) study.
Topics: Adolescent; Adult; Aged; Antihypertensive Agents; Blood Glucose; Female; Humans; Hydrochlorothiazide | 2009 |
Thiazide diuretics alone or with beta-blockers impair glucose metabolism in hypertensive patients with abdominal obesity.
Topics: Adrenergic beta-Antagonists; Atenolol; Diabetes Mellitus; Diuretics; Drug Therapy, Combination; Fast | 2010 |
[Hyperglycemic effect by means of salidiuretics in diabetes mellitus].
Topics: Chlorthalidone; Diabetes Mellitus; Humans; Hydrochlorothiazide; Hyperglycemia | 1962 |
Actiological factors in benzothiadiazine hyperglycemia.
Topics: Benzothiadiazines; Hydrochlorothiazide; Hyperglycemia; Thiazides | 1963 |
THE HYPERGLYCEMIC EFFECT OF HYPOTENSIVE DRUGS.
Topics: Antihypertensive Agents; Benzothiadiazines; Black People; Blood Glucose; Diazoxide; Guanethidine; Hu | 1964 |
DIURETIC THERAPY. VI. METABOLIC COMPLICATIONS OF THIAZIDE THERAPY AND THEIR CORRECTION.
Topics: Bendroflumethiazide; Blood; Blood Urea Nitrogen; Diuretics; Humans; Hydrochlorothiazide; Hyperglycem | 1964 |
ETIOLOGICAL FACTORS IN THIAZIDE-INDUCED OR AGGRAVATED DIABETES MELLITUS.
Topics: 17-Hydroxycorticosteroids; 17-Ketosteroids; Amylases; Blood Chemical Analysis; Blood Urea Nitrogen; | 1965 |
Hyperglycemic reaction to a hydrochlorothiazide.
Topics: Chlorothiazide; Hydrochlorothiazide; Hyperglycemia | 1960 |
Thiazide diuretics exacerbate fructose-induced metabolic syndrome.
Topics: Allopurinol; Animals; Blood Pressure; Body Weight; Diuretics; Fructose; Gout Suppressants; Hydrochlo | 2007 |
Acute diuretic induced hyperglycaemia in rats.
Topics: Acetazolamide; Adrenalectomy; Animals; Bendroflumethiazide; Chlorthalidone; Ergotamine; Ethacrynic A | 1967 |
Some wrong-way chemical changes during antihypertensive treatment: comparison of indapamide and related agents.
Topics: Adult; Antihypertensive Agents; Chemical Phenomena; Chemistry; Chlorthalidone; Diuretics; Humans; Hy | 1983 |
A fixed combination of hydrochlorothiazide and amiloride for the treatment of essential hypertension.
Topics: Adolescent; Adult; Aged; Amiloride; Blood Chemical Analysis; Blood Pressure; Body Weight; Drug Thera | 1980 |
Hyperglycemia and diabetic coma: possible relationship to diuretic-propranolol therapy.
Topics: Diabetic Coma; Diuretics; Drug Therapy, Combination; Humans; Hydrochlorothiazide; Hyperglycemia; Hyp | 1979 |
[Abnormal glucose tolerance induced by drugs and chemicals].
Topics: Adrenergic beta-Antagonists; Asparaginase; Calcium Channel Blockers; Contraceptives, Oral; Cyclospor | 1991 |
[Side effects of treatment of arterial hypertension with hypothiazide].
Topics: Adult; Diuretics; Female; Humans; Hydrochlorothiazide; Hyperglycemia; Hyperlipidemias; Hypertension; | 1985 |
[Studies in the rat on the problem of the diabetogenic effect of saluretics].
Topics: Acetazolamide; Animals; Benzothiadiazines; Blood Glucose; Chlorthalidone; Diazoxide; Glucose Toleran | 1965 |
[The effect of hydrochlorthiazide on the blood sugar-increasing action of diazoxide].
Topics: Animals; Antihypertensive Agents; Carbohydrate Metabolism; Diazoxide; Hydrochlorothiazide; Hyperglyc | 1966 |
Hyperglycemic hyperosmolar coma associated with hydrochlorothiazide and pancreatitis.
Topics: Aged; Coma; Female; Humans; Hydrochlorothiazide; Hyperglycemia; Osmolar Concentration; Pancreatitis | 1972 |
Effect of single dose administration of diuretics on the blood sugar of alloxan-diabetic mice or mice made hyperglycaemic by the acute administration of diazoxide.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Diazoxide; Diuresis; Diuretics; Drug Intera | 1973 |
Effect of diuretics on mouse blood sugar following single dose administration.
Topics: Adrenalectomy; Animals; Blood Glucose; Ergotamine; Ethacrynic Acid; Female; Furosemide; Glucose Tole | 1971 |
Effect of hydrochlorothiazides on blood sugar level in diabetics and nondiabetics.
Topics: Diabetes Mellitus; Humans; Hydrochlorothiazide; Hyperglycemia | 1969 |
[Data on the mechanism of the diabetogenic effect of chlorothiazides].
Topics: Animals; Chlorothiazide; Diazoxide; Furosemide; Gluconeogenesis; Hydrochlorothiazide; Hyperglycemia; | 1967 |
[Research on hyperglycemia caused by saluretics].
Topics: Diabetes Mellitus; Diuresis; Diuretics; Electrolytes; Female; Furosemide; Heart Diseases; Humans; Hy | 1967 |